Biography:Geoffrey von Maltzahn
Geoffrey von Maltzahn | |
|---|---|
| Born | July 22, 1980 |
| Nationality | American |
| Alma mater | Massachusetts Institute of Technology (S.B., 2003) University of California, San Diego (M.S., 2005) Massachusetts Institute of Technology (Ph.D. 2010) |
| Known for | Microbiome therapeutics, microbiome agriculture, communicating nanoparticles |
| Awards | Lemelson-MIT Student Prize (2009) National Inventors Hall of Fame Collegiate Inventors Competition Graduate Prize (2009), Massachusetts Institute of Technology Randolph G Wei Award (2003) |
| Scientific career | |
| Fields | Microbiome, Microbiology, Nanotechnology, Microbiome Agriculture, Synthetic Biology |
| Academic advisors | Sangeeta N. Bhatia, Shuguang Zhang |
Geoffrey von Maltzahn, Ph.D. (born July 22, 1980) is an American biological engineer and entrepreneur in biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Kaleido Biosciences, Seres Therapeutics, Axcella Health and Sienna Biopharmaceuticals.[1] He is an inventor with 200 bioengineering and biotechnology patents and applications[2][3] while has co-authored more than 20 peer-reviewed publications.[4] He is a partner at Flagship Pioneering, a Massachusetts-based firm that funds start-ups in the healthcare and agriculture industries.[5]
Early life and education
Geoffrey von Maltzahn was born in Arlington, Texas, and subsequently moved to Alexandria, Virginia. He was awarded his S.B. in Chemical Engineering from the Massachusetts Institute of Technology (MIT) in 2003, his Master of Science degree in Bioengineering from the University of California, San Diego in 2005, and his PhD from the Harvard–MIT Division of Health Sciences and Technology at the Massachusetts Institute of Technology in 2010.[6][7]
Career
In 2009, Geoffrey von Maltzahn joined Flagship Pioneering, where he focuses on inventing and building new life science companies. In the same year, he co-founded Axcella Health, a company focused on developing amino acid therapeutics. In 2010, he co-founded Seres Therapeutics[8] and served as the Chief Technology Officer.[9][10] In 2013, he co-founded Indigo Agriculture, a company focused on improving the microbiome of modern crops and is currently Chief Innovation Officer.[11] In 2015, he founded Kaleido Biosciences, is a clinical-stage biotechnology company engaged in the development of the microbiome. Until 2017, he served as the CEO of the company.
Awards and recognitions
- Business Insider’s 30 Biotech Leaders Under 40 - 2017[12]
- MSNBC’s Inventions of the Year - 2009[13]
See also
Indigo Agriculture
David Perry
References
- ↑ Meet the 30 biotech leaders under 40 who are searching for breakthrough treatments and shaping the future of medicine Business Insider Retrieved 9 October 2017
- ↑ Patents by Inventor Geoffrey von Maltzahn Justia Patents
- ↑ Patents as Early Indicators of Technology and Investment Trends Frontiers - figure 3 Retrieved 20 June 2018
- ↑ Geoffrey von Maltzahn at Bloomberg Bloomberg
- ↑ Flagship Pioneering Unveils Kaleido Biosciences and First Chemistry Platform for Microbiome Health Market Insider Retrieved 18 September 2017
- ↑ Geoffrey von Maltzahn MIT
- ↑ Geoffrey von Maltzahn at Bloomberg Bloomberg
- ↑ Term Sheet Fortune Retrieved 21 July 2016
- ↑ Seres Therapeutics IPO Soars, Raises $133 Million Investors Business Daily Retrieved 26 June 2015
- ↑ Seres at Crunchbase Crunchbase
- ↑ Indigo Agriculture on CNBC CNBC
- ↑ "30 Under 40 Leaders in Biotech Pharma 2017". http://www.businessinsider.com/30-under-40-leaders-in-biotech-pharma-2017-10#geoffrey-von-maltzahn-37-wants-to-rethink-the-way-we-treat-diseases-by-focusing-on-the-microbes-that-live-inside-us-16. Retrieved 2017-10-09.
- ↑ "MSNBC's Inventions of the Year". http://www.nbcnews.com/id/33628472/ns/technology_and_science-innovation/?pg=3#Tech_Innovation_Awards. Retrieved 2017-10-09.
 |
